Alteration of retinol-binding-protein concentrations by the synthetic retinoid fenretinide in healthy human subjects.
Normal subjects received fenretinide (HPR), 200 mg/d, on three schedules. Schedule 1 was treatment for 28 d. Schedule 2 consisted of 14 d of treatment, 3 d hiatus, and a second drug course of 14 d, 10,000 IU vitamin A was administered during the 3-d hiatus. Schedule 3 was 14 d of treatment followed by a rest period of 7 d and then 14 d of treatment. Increase in plasma HPR was accompanied by an even higher increase in the metabolite N-(4-methoxyphenyl)-all-trans-retinamide (MPR). The administration of HPR was associated with a significant reduction in retinol-binding protein (RBP), which returned to pretreatment values after the drug treatment was discontinued. Reduction of plasma retinol was also observed. Use of interrupted schedules with resting periods of 3 and 7 d changed HPR, MPR, and RBP concentrations in plasma. Addition of vitamin A did not affect the pattern of the measured variables in the plasma.
Dimitrov
N V
NV
Department of Medicine, Michigan State University, East Lansing 48824.
Meyer
C J
CJ
Perloff
M
M
Ruppenthal
M M
MM
Phillipich
M J
MJ
Gilliland
D
D
Malone
W
W
Minn
F L
FL
D000328:Adult; D004334:Drug Administration Schedule; D005260:Female; D017313:Fenretinide; D006801:Humans; D008297:Male; D012177:Retinol-Binding Proteins / Q000378:metabolism*; D054839:Retinol-Binding Proteins, Plasma; D014212:Tretinoin / Q000031:analogs & derivatives* / Q000378:metabolism / Q000493:pharmacokinetics / Q000494:pharmacology; D014801:Vitamin A / Q000097:blood
D012177:Retinol-Binding Proteins; D054839:Retinol-Binding Proteins, Plasma; D014801:Vitamin A; D017313:Fenretinide; D014212:Tretinoin; C058346:N-(4-methoxyphenyl)retinamide